Wall Street analysts forecast that MeiraGTx Holdings PLC (NASDAQ:MGTX) will report earnings of ($0.46) per share for the current quarter, Zacks reports. Zero analysts have made estimates for MeiraGTx’s earnings. The company is scheduled to report its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that MeiraGTx will report full-year earnings of ($4.17) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($4.06) per share, with EPS estimates ranging from ($4.15) to ($3.97). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover MeiraGTx.
MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($2.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($1.62).
Several brokerages recently weighed in on MGTX. Zacks Investment Research downgraded MeiraGTx from a “hold” rating to a “sell” rating in a research note on Wednesday, September 12th. Barclays began coverage on MeiraGTx in a research note on Tuesday, July 3rd. They set an “overweight” rating and a $20.00 target price for the company. Evercore ISI began coverage on MeiraGTx in a research note on Monday, July 9th. They set an “outperform” rating and a $21.00 target price for the company. Chardan Capital began coverage on MeiraGTx in a research note on Thursday, August 23rd. They set a “buy” rating for the company. Finally, Bank of America began coverage on MeiraGTx in a research note on Tuesday, July 3rd. They set a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $20.50.
Large investors have recently made changes to their positions in the stock. Luminus Management LLC bought a new stake in MeiraGTx during the 2nd quarter valued at approximately $2,267,000. Dean Capital Investments Management LLC bought a new stake in MeiraGTx during the 2nd quarter valued at approximately $458,000. Point72 Asset Management L.P. bought a new stake in MeiraGTx during the 2nd quarter valued at approximately $229,000. Millennium Management LLC bought a new stake in MeiraGTx during the 2nd quarter valued at approximately $923,000. Finally, FMR LLC bought a new stake in MeiraGTx during the 2nd quarter valued at approximately $664,000. Hedge funds and other institutional investors own 22.76% of the company’s stock.
Shares of NASDAQ MGTX traded down $0.06 during mid-day trading on Friday, reaching $13.37. 25,696 shares of the company traded hands, compared to its average volume of 66,026. MeiraGTx has a fifty-two week low of $7.98 and a fifty-two week high of $15.49.
MeiraGTx Company Profile
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases.
Recommended Story: Average Daily Trade Volume Explained
Get a free copy of the Zacks research report on MeiraGTx (MGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.